Search Results

Displaying Results 1-1 of 1 "'NTZ'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight

Dec 08, 2025, 17:31 ET Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight

anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as Genfit's VS-01, G1090N (reformulation of NTZ), SRT-015, CLM-022, VS-02-HE, Yaqrit's YAQ005, Grifols Therapeutics' ALBUTINE (Albumin 5%), and others, and healthcare spending in the 7MM.

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.